| Name | fibroblast growth factor 23 |
|---|---|
| Synonyms | ADHR; HYPF; FGF 23; FGF23; Fibroblast growth factor 23; Fibroblast growth factor 23 precursor; HPDR 2; HPDR2… |
| Name | phosphorus |
|---|---|
| CAS | phosphorus |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 20059333 | Bergwitz C, Juppner H: Regulation of homeostasis by PTH, and FGF23. . Annu Rev Med. 2010;61:91-104. Fibroblast growth factor 23 (FGF23) is part of a previously unrecognized hormonal bone-parathyroid-kidney axis, which is modulated by PTH, 1,25 (OH)(2)- (1,25 (OH)(2) D), dietary and serum phosphorus levels. |
65(0,2,2,5) | Details |
| 19546009 | Fukumoto S, Martin TJ: Bone as an endocrine organ. Trends Endocrinol Metab. 2009 Jul;20(5):230-6. Epub 2009 Jun 21. Although bone has long been recognized as a target for hormones influencing and phosphorus homeostasis and bone structure, recent evidence shows that the skeleton itself produces at least two hormones, fibroblast growth factor 23 (FGF23) and osteocalcin. |
62(0,2,2,2) | Details |
| 19770756 | Wolf M: Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens. 2009 Nov;18(6):463-8. RECENT FINDINGS: FGF23 regulates phosphorus and metabolism. |
41(0,1,2,6) | Details |
| 19965919 | Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H: Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010 Feb;95(2):578-85. Epub 2009 Dec 4. Context: Fibroblast growth factor 23 (FGF23) regulates phosphorus homeostasis and metabolism. |
40(0,1,1,10) | Details |
| 20012997 | Wesseling-Perry K: FGF-23 in bone biology. Pediatr Nephrol. 2010 Apr;25(4):603-8. Epub 2009 Dec 15. Recent studies have demonstrated that levels of fibroblast growth factor 23 (FGF-23), a key regulator of phosphorus and metabolism, rise dramatically as renal function declines and may play a key initiating role in disordered mineral and bone metabolism in patients with chronic kidney disease (CKD). |
31(0,1,1,1) | Details |
| 19515808 | Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M: FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol. 2009 Aug;297(2):F282-91. Epub 2009 Jun 10. Similarly, in FGFR4 (-/-) mice, administration of FGF23 caused a small but significant decrease in serum phosphorus levels (8.7 +/- 0.3 vs. 7.6 +/- 0.4 mg/dl; p < or = 0.001) and in renal BBM NaPi-2a and NaPi-2c protein abundance. |
11(0,0,1,6) | Details |
| 19436134 | Kusano K, Saito H, Segawa H, Fukushima N, Miyamoto K: Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats. J Nutr Sci Vitaminol. 2009 Apr;55(2):99-105. FGF23 is a circulating factor that regulates renal phosphorus reabsorption and 1 alpha-hydroxylase activity. |
19(0,0,2,9) | Details |
| 19339809 | Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T: Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009;111(4):p59-66. Epub 2009 Apr 1. METHOD:We measured plasma parameters in uremic rats fed a high-phosphorus diet and then performed parathyroidectomy (PTX) to determine its effect. |
8(0,0,0,8) | Details |
| 19414634 | Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009 May 19;119(19):2545-52. Epub 2009 May 4. BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. |
7(0,0,1,2) | Details |
| 20146335 | Kobayashi K, Nakao K, Kawai K, Ito K, Hukumoto S, Asakage T, Oota S, Motoi R: Tumor-induced osteomalacia originating from the temporal bone: A case report. Head Neck. 2010 Feb 9. Fibroblast growth factor 23 (FGF-23) mRNA is overexpressed in the tumor tissue, leading to impaired reabsorption of phosphorus in the renal tubules and hypophosphatemia. |
6(0,0,1,1) | Details |
| 19322138 | El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, Ingalls CM, Liao HW, Giachelli CM: feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009 Jun;75(12):1297-307. Epub 2009 Mar 25. |
6(0,0,1,1) | Details |
| 19666939 | Khadilkar A, Mughal MZ, Hanumante N, Sayyad M, Sanwalka N, Naik S, Fraser WD, Joshi A, Khadilkar V: Oral supplementation reverses the biochemical pattern of parathyroid hormone resistance in underprivileged Indian toddlers. Arch Dis Child. 2009 Dec;94(12):932-7. Epub 2009 Aug 9. Serum concentrations of ionised phosphorus, PTH and fibroblast growth factor-23 (FGF-23) were measured at the start and end of the trial. |
6(0,0,1,1) | Details |
| 19411468 | Masi L, Gozzini A, Franchi A, Campanacci D, Amedei A, Falchetti A, Franceschelli F, Marcucci G, Tanini A, Capanna R, Brandi ML: A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis. J Bone Joint Surg Am. 2009 May;91(5):1190-8. Phosphatonins are important hormones that regulate phosphorus homeostasis. |
5(0,0,0,5) | Details |
| 19628670 | Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, Fernandez-Martin JL, Naves-Diaz M, Cannata-Andia JB: Indirect regulation of PTH by estrogens may require FGF23. . J Am Soc Nephrol. 2009 Sep;20(9):2009-17. Epub 2009 Jul 23. treatment significantly decreased serum 1,25 (OH)(2) (3) and phosphorus levels. |
4(0,0,0,4) | Details |
| 19483275 | Goto S, Fukagawa M: [Clinical aspect of recent progress in metabolism. Clin Calcium. 2009 Jun;19(6):809-14. Fibroblast growth factor (FGF) 23, which is the novel phosphaturic hormone, increases in patients with chronic kidney disease. |
2(0,0,0,2) | Details |
| 20176609 | Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA: Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010 Feb 22. Intact FGF-23, parathormone, lipids, and phosphorus were measured. |
2(0,0,0,2) | Details |
| 19483271 | Inoue D: [Clinical aspect of recent progress in metabolism. Clin Calcium. 2009 Jun;19(6):778-84. In human body phosphorus is mostly stored with in bone as hydroxyapatite in dynamic equilibrium with the extracellular fluid compartment. After identification of FGF23 our understanding of metabolism has profoundly improved. |
2(0,0,0,2) | Details |
| 19569031 | Tsagalis G, Psimenou E, Manios E, Laggouranis A: Fibroblast growth factor 23 (FGF23) and the kidney. . Int J Artif Organs. 2009 Apr;32(4):232-9. |
2(0,0,0,2) | Details |
| 19371801 | Patel TV, Singh AK: Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions. Semin Nephrol. 2009 Mar;29(2):105-12. In the past 5 years, with the publication of several randomized controlled trials, large observational studies, and smaller clinical series, significant progress has been made in our understanding of mineral metabolism, and phosphorus management, and the use of activated irrespective of parathyroid hormone level in chronic kidney disease. More recently, fibroblast growth factor-23 and serum alkaline phosphatase have been shown to predict mortality in dialysis patients, making these attractive markers to monitor. |
1(0,0,0,1) | Details |
| 19295198 | Nikolov IG, Mozar A, Drueke TB, Massy ZA: Impact of disturbances of and metabolism on vascular calcification and clinical outcomes in patients with chronic kidney disease. Blood Purif. 2009;27(4):350-9. Epub 2009 Mar 18. Hypercalcemia and hyperphosphatemia have long been known to play a major role in the occurrence of vascular and other soft tissue calcification in patients with CKD, together with endocrine disturbances including parathyroid hormone, fibroblast growth factor-23, and klotho. It remains to be demonstrated in prospective randomized trials whether normalization of serum phosphorus and/or leads to better patient outcome. |
1(0,0,0,1) | Details |
| 19295196 | Cozzolino M, Ciceri P, Volpi EM, Olivi L, Messa PG: Pathophysiology of and metabolism impairment in chronic kidney disease. Blood Purif. 2009;27(4):338-44. Epub 2009 Mar 18. However, in the presence of low high phosphorus, deficiency, and uremia, PT cells leave quiescence. Furthermore, recent studies indicate that the fibroblast growth factor-23 may play a central role in the regulation of phosphate-vitamin D metabolism in CKD. |
1(0,0,0,1) | Details |
| 19371800 | Williams ME: Chronic kidney disease/bone and mineral metabolism: the imperfect storm. Semin Nephrol. 2009 Mar;29(2):97-104. Some key current issues that are reviewed here are as follows: (1) factors promoting SHPT, (2) the role of fibroblast growth factor-23 in CKD/BMD, (3) molecular mechanisms of SHPT, (4) mechanisms of vascular calcification, and (5) medical management of the disorder, including calcimimetics. |
1(0,0,0,1) | Details |
| 19615558 | McKay CP, Portale A: Emerging topics in pediatric bone and mineral disorders 2008. Semin Nephrol. 2009 Jul;29(4):370-8. The calcium sensing receptor (CaSR) and fibroblast growth factor 23 (FGF-23) play central roles in the regulation of and phosphorus metabolism, respectively. The calcium sensing receptor (CaSR) and fibroblast growth factor 23 (FGF-23) play central roles in the regulation of and phosphorus metabolism, respectively. |
1(0,0,0,1) | Details |
| 19563382 | Jorgetti V: Review article: Bone biopsy in chronic kidney disease: patient level end-point or just another test?. Nephrology. 2009 Jun;14(4):404-7. The reduction of renal function in chronic kidney disease leads to disturbed and phosphorus metabolism, impaired action of increased parathyroid hormone, FGF-23 levels and ultimately bone disorders. The reduction of renal function in chronic kidney disease leads to disturbed and phosphorus metabolism, impaired action of increased parathyroid hormone, FGF-23 levels and ultimately bone disorders. |
1(0,0,0,1) | Details |
| 19606082 | Isakova T, Gutierrez OM, Wolf M: A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int. 2009 Oct;76(7):705-16. Epub 2009 Jul 15. Perhaps even more important, the discovery of fibroblast growth factor 23 (FGF23) and its potential as a novel diagnostic to identify disordered phosphorus metabolism at an early, subclinical state has presented the opportunity to develop placebo-controlled randomized trials in pre-dialysis CKD patients with normal serum levels. |
1(0,0,0,1) | Details |